ascendis transcon glp-1 program Pharma has granted Novo Nordisk an exclusive worldwide license for the platform to develop and commercialize products for metabolic diseases, including obesity and type 2 diabetes, along with a product-specific Novo Nordisk taps Ascendis in
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2





















![Once-Monthly Incretin-, Amylin-, and THRβ-Targeting Therapies for Type 2 Diabetes and Obesity: Clinical Evidence and Development Pipelines[v1]](https://www.preprints.org/frontend/manuscript/8f0b88ff05d9221c0624fab564ba2637/download_pub/figure/graphic_abstract.jpg)

